Voyager Therapeutics Inc
Suletud
3.33 -7.5
Ülevaade
Aktsiahinna muutus
24h
Min
3.3
Max
3.62
Sissetulek | -511K -28M |
|---|---|
Müük | -13M 2.6M |
Aktsiakasum | -0.47 |
Kasumimarginaal | -1,077.401 |
Töötajad | 141 |
EBITDA | -455K -29M |
Soovitused | Tugev "osta" hinnang |
|---|---|
12 kuu keskmine prognoos | +318.23% upside |
Järgmine tulemuste avaldamine | 4. aug 2026 |
|---|
Turukapital | -5.4M 229M |
|---|---|
Eelmine avamishind | 10.83 |
Eelmine sulgemishind | 3.33 |
Voyager Therapeutics Inc Graafik
Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.
Seotud uudised
Võrdlus sarnastega
Hinnamuutus
Voyager Therapeutics Inc Prognoos
Hinnasiht
By TipRanks
318.23% tõus
12 kuu keskmine prognoos
Keskmine 15.14 USD 318.23%
Kõrge 25 USD
Madal 8 USD
Põhineb 9 Wall Streeti analüütiku instrumendi Voyager Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.
Finantsandmed
Müügi- ja halduskulud
Tegevuskulud
Maksueelne kasum
Müük
Müügikulu
Brutokasum müügist
Intressikulud võla pealt
EBITDA
Ärikasum
$
Ettevõttest Voyager Therapeutics Inc
Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.
